This study investigates the effects of increased NH 3 or amino acid supply on glutamine utilisation and production by the splanchnic tissues of fed sheep. Six sheep, prepared with vascular catheters in the aorta, mesenteric, portal and hepatic veins, were fed grass pellets to 1·1 £ energy maintenance requirements. Each treatment involved a 4 d abomasal infusion, of either ammonium bicarbonate (AMM; 23·4 mmol/kg 0·75 per min), water (CONT), or a mixture of amino acids that excluded glutamine and glutamate (AA; 46·8 mmol amino acid-N/kg 0·75 per min). The treatments simulated nutritional extremes in terms of the balance of absorbed N. Kinetics across the whole gut and the liver were monitored during an intra-jugular infusion of [5-15 N]glutamine. Blood flow across the whole gut or liver were unaffected by treatment. Both AMM and AA infusions doubled the hepatic release of urea-N compared with CONT (P,0·02). AA infusion decreased arterial glutamine concentration by 26 % (P,0·01) and 23 % (P,0·05) compared with AMM and CONT respectively. Despite this, whole-body glutamine flux was not affected by treatment. In contrast, AMM infusion increased hepatic glutamine production by 40 % compared with CONT (P,0·02). This provided a mechanism to ensure NH 3 supply to the periphery was maintained within the normal low physiological levels. Hepatic glutamine utilisation tended to increase during AA infusion, probably to ensure equal inflows of N to the ornithine cycle. Between 6 and 10 % of NH 3 absorbed across the digestive tract was derived from the amido-N of glutamine. Overall, splanchnic glutamine utilisation accounted for 45 -70 % of whole-body glutamine flux.
Glutamine is now recognised as an extremely important amino acid, with key roles as a N precursor for synthesis of nucleic acids and amino sugars (Garber, 1980) ; as a preferred fuel for cells of the intestinal mucosa (Souba, 1991) ; and an obligate nutrient for the immune system (Calder, 1994) . Additional functions include involvement in maintenance of acid-base balance (Meijer et al. 1990 ); prevention of peripheral hyperammonaemia (Häussinger et al. 1992) ; and a putative role in regulation of cellular macronutrient metabolism (vom Dahl & Häussinger, 1996) . Alteration of glutamine status, therefore, may have marked effects on whole-body metabolism.
In non-ruminant animals, increased hepatic extraction of glutamine occurs when amino acid supply is in excess of the requirement for tissues (Meijer et al. 1990; Häussinger et al. 1992) . This is to provide sufficient NH 3 to maintain ornithine-cycle activity and allow catabolism of the amino acid surplus. In ruminant animals, however, rumen fermentation normally results in excess NH 3 production and limited amino acid available for absorption. Under these circumstances, hepatic glutamine net production may occur, this time as a mechanism to detoxify NH 3 (WrayCahen et al. 1997) . This putative species difference may also extend to the use of glutamine by the digestive tract where, in fasted animals, the limited result available suggest that more glutamine is catabolised to NH 3 in rats than sheep (cf. Windmueller & Spaeth, 1980; Gate et al. 1999) . In the case of the rat, such elevation in NH 3 production at non-hepatic sites, may assist the hepatic removal of amino acid excesses. In contrast, when NH 3 availability is already plentiful, as is the case for the ruminant animal due to microbial fermentation in the foregut, avoidance of NH 3 excess is desirable because of the known metabolic toxicity (see Lobley et al. 1995) .
The hypotheses described earlier, and implied species differences, are based on limited information, however. This is particularly so when the metabolic involvement of the amido(5)-N is considered. This moiety is key to a number of the reactions described and yet, even in nonruminant animals, only a few studies in vivo have been conducted (e.g. Darmaun et al. 1986; Cooper et al. 1988) . Until recently, the studies of Heitmann & Bergman (1978) were the only source of data available for kinetics of glutamine fluxes across the splanchnic tissues; the information, however was restricted to the C-skeleton metabolism through use of [ 14 C]glutamine. Some information on the metabolic fate of the 5-N of glutamine across the digestive tract of sheep is now available (Gate et al. 1999) , but this is only for fasted lambs.
Removal of excesses of either NH 3 and/or amino acids is universally recognised as important to all animals, but what is less clear are the possible implications for glutamine requirement and status. The current study was designed, therefore, to test whether the glutamine-based mechanisms for controlling entry of excess NH 3 or amino acids into the ornithine cycle described for non-ruminant animals also operate in sheep. The protocol simulated nutritional extremes by providing, through chronic (4 d) abomasal infusion, either ammonium bicarbonate (AMM) or a mixture of amino acids (AA) in addition to a basal diet (CONT).
Materials and methods

Animals and diets
Six Suffolk cross wether sheep (mean live weight 39 SD 3·1 kg,) were surgically prepared with chronic indwelling catheters in the aorta and portal, hepatic and mesenteric veins, as described previously ). An additional Degania silicone rubber catheter (1·5 mm i.d., 3·2 mm outer diameter; Merck Ltd, Poole, Dorset, UK) was implanted directly in the abomasum to allow postrumen infusions. Animals were allowed at least 3 weeks recovery after surgery before allocation to the experiment, at which time a temporary polyvinly chloride catheter (0·8 mm i.d., 1·5 mm outer diameter; Critchley Electrical Products, Auburn, New South Wales, Australia) was inserted into an exterior jugular vein.
Animals were adapted to metabolic cages and offered 47 g grass pellets/kg 0·75 per d (1·1 £ energy maintenance requirements) (grass pellets contained:10·5 MJ metabolisable energy/kg DM; 22·0 g N/kg DM; 960 g DM/kg), supplied from automated feeders as hourly portions.
Experimental design
For each animal the experimental protocol involved three consecutive abomasal infusions of ammonium bicarbonate (AMM; 365 mmol/min, 23·4 mmol/kg 0·75 per min), an L-amino acid mixture (AA; based on rumen microbial protein composition, as described previously , at a rate of 730 mmol amino acid-N/min (46·8 mmol AA-N/kg 0·75 per min)) and water (CONT). The AMM and AA infusates were prepared in water. Three animals were infused in the order AMM, CONT, AA while the other three received the reverse sequence (AA, CONT, AMM). Each infusion was for 4 d at a rate of 60 g/h, allowing at least 10 d between the AMM and AA treatments. The CONT infusion was allocated in the middle of the other two treatments to allow maximum time spacing between AA and AMM infusion, and was started at least 3 d after finishing the previous treatment.
The amounts infused were designed to obtain a relationship for liver uptake of NH 3 -N: amino acid-N of approximately 2:1 for the AMM infusion, and 1:2 for the AA respectively, assuming this relationship was approximately 1:1 in the case of water infusion (CONT), according to previous observations in animals under similar conditions (Milano, 1997) and assuming that half the amount of amino acid-N infused reached the liver. The infusions were also calculated to maintain urea production below the maximum hepatic capacity (approximately 2 mmol urea N/g liver per min; Symonds et al. 1981; Orzechowski et al. 1987) .
Stable isotope infusion
Pyrogen-free L-glutamine solution (36 mM in sterile 0·15 M -NaCl; BUFA bv, Spodefell Ltd, London, UK) was infused into the jugular catheter at a rate of 6 mmol/min during the first 3 of treatment. This was to avoid changes in glutamine pool sizes or fluxes when the [ 15 N]glutamine was infused. On the fourth day the L-glutamine infusion was substituted by 100 ml 24 mM [5- 15 N]glutamine (99 atom %; Mass Trace Inc., Woburn, MA, USA) that contained 60 kU sodium heparin (CP Pharmaceuticals, Wrexham, Wales, UK), and which was infused at 6 mmol/min (15 g/h) for 6 h. Over the same period a sterile solution of 0·1 M-sodium p-aminohippurate in 0·05 M-sodium phosphate buffer (final pH 7·4) was infused into the mesenteric vein at 40 g/h to measure blood flow through splanchnic tissues.
Sample collection
Over 1 h intervals, between 2 and 6 h of [5- 15 N]glutamine infusion, blood was continuously withdrawn from the aorta and hepatic and portal veins (each 12 ml/h) as described previously . Blood samples for determination of metabolite natural abundance were taken 24 h before the start of each infusion of [5- 15 N]glutamine.
Chemical analyses
Analyses of blood pH and pO 2 were performed on an ABL3 Blood Gas Analyzer (Radiometer, Copenhagen, Denmark) and packed cell volume was determined by haematocrit. Blood samples were maintained on ice and centrifuged at 1000 g for 15 min at 48C to prepare plasma. Blood and plasma DM were obtained by freeze-drying known weights of material (blood was first haemolysed by a 1:1 addition of water). Plasma flow (g/min) was determined gravimetrically by downstream dilution of p-aminohippurate . Plasma glutamine and urea concentrations were determined by isotope dilution (Milano et al. 2000) following addition of known amounts of 0·75 mmolal [5- 15 N]glutamine and 3 mmolal [ 15 N 2 ]urea (99 atom %; Isotec Ltd, Miamisburg, OH, USA), with the mixture stored at 2208C until analysis. Enrichments of glutamine (in isolated plasma and from isotope dilution) and urea (isotope dilution only) were determined as the tributyldimethylsilyl derivatives (Calder & Smith, 1988) and analysed by GC -MS in the electron impact mode. For [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] N]glutamine enrichment, fragment ions of m/z 168 and 169 were monitored; these contain 15 N associated only with the 5-N (amide) group (Williams & Wolfe, 1994) . For urea concentration, fragment ions of m/z 231 and 233 were monitored. Incorporation of 15 N into urea in vivo were too low to be detected by GC -MS approaches, so these were determined by GC -combustion MS, as described previously (Obitsu et al. 2000) .
NH 3 concentration was measured in fresh plasma using a Kone Dynamic selective Analyzer (Kone Instruments, Espoo, Finland) by the glutamate dehydrogenase reaction. 15 NH 3 enrichment was determined by enzymatic conversion (glutamate dehydrogenase) of plasma NH 3 to norvaline, following the procedure described by Nieto et al. (1996) .
Calculations and statistics
For blood transactions, blood flow (BF) was calculated from plasma flow (PF) and packed cell volume (PCV) as:
Blood O 2 content was determined from haemoglobin content and saturation (see Lobley et al. 1995) . Mass transfers of metabolites across the portal -drained viscera (PDV) and liver were calculated as:
respectively, where PF is hepatic portal vein plasma (or blood) flow, HF is hepatic vein plasma (or blood) flow and AF is hepatic artery plasma (or blood) flow (calculated as the difference between hepatic vein and portal vein flows, i.e. HF 2 PF); and C a , C p and C h represent the concentrations of metabolites in the artery, hepatic portal and hepatic vein plasma respectively. Similarly, isotope transfers (utilisation) across PDV and liver were determined as:
and
respectively, where E is the enrichment (mol % excess) of the metabolite in the appropriate plasma sample. These isotope transfers were converted to glutamine movements by division with the assumed precursor. In this case, the glutamine enrichment in the venous outflow was chosen (P for PDV; and H for liver). PDV and hepatic productions of glutamine were calculated as the sum of utilisation plus net glutamine transfer and represents de novo glutamine production plus glutamine from protein degradation.
The 5-N glutamine whole-body irreversible loss rate (ILR or flux) was calculated as:
where E i and I represent the enrichment (mol % excess) and rate of infusion (mmol/min) of the [5- 15 N]glutamine infusate respectively. When the proportion of wholebody ILR attributable to the organs was estimated, all the transfers were calculated based on the common precursor, arterial glutamine enrichment. Blood NH 3 concentration was assumed equal to that in plasma (Milano, 1997) . Urea transfers were calculated based on blood water flow and plasma water urea concentration . Data were subjected to two -way ANOVA (Genstat for Windows, release 3·2; Lawes Agricultural Trust, Rothamsted, Herts, UK), with animals treated as blocks, for the effect of treatment (AMM, CONT and AA) and period. The experimental design adopted allowed eight residual d.f. for all analyses. In most instances, period was found to be not significant and all data were re-analysed by one-way ANOVA, with ten residual d.f. for a full data set (except for indicated missing values). Significance between treatments was assessed by Fisher's least significant difference procedure. For comparisons of different variables within one treatment, one-way ANOVA was also used.
Results
Animals showed normal behaviour during all infusions.
Initial preliminary studies revealed occasional increases in body temperature (1·0 -1·58C) when unlabelled L-glutamine from different commercial sources was infused. This problem disappeared with introduction of the pyrogen-free grade L-glutamine. For all animals, each value represents the mean of the four hourly integrated measurements, except for one sheep where, during the AA infusion, only three sampling points were used due to problems with one sample. For another sheep, during infusion CONT, the data are based on two integrated 1 h samples because of difficulties in withdrawal of blood from the portal catheter. Blood, and plasma, flows (g/min) were not significantly different between the treatments (Table 1 ). The mean value obtained for hepatic artery flow was 6 % (range 2 -9 %) of total hepatic flow, comparable with previous observations .
In all the blood samples, pH was unchanged by treatment (results not shown). Arterial pH remained .7·4 for all infusions, thus mild acidosis associated with other ammonium salts (e.g. the chloride; Lobley et al. 1995) was avoided. O 2 consumptions by PDV and liver were of similar magnitude and not significantly affected by treatment (Table 1) .
Ammonia and urea concentrations and transfers
NH 3 concentrations in arterial or hepatic venous plasma were not significantly affected by treatment (Table 2) . During infusion of AMM, hepatic portal venous NH 3 concentrations were higher than during CONT or AA infusion (increased by þ82 and þ37 % respectively, P,0·01). Hepatic portal NH 3 concentrations were also greater during AA compared with CONT infusion (P,0·05). Both NH 3 appearance across the PDV (P,0·01) and liver removal (P,0·05) were significantly increased by AMM treatment (Table 3) . Compared with CONT, the net increase in PDV NH 3 appearance during AMM infusion of 389 mmol NH 3 /min was close to the amount infused (365 mmol NH 3 /min). Net liver NH 3 removal tended to exceed net NH 3 PDV appearance in CONT and AA infusions. This indicates a contribution of peripheral tissues to NH 3 production, as was reflected in the greater differential in NH 3 concentrations between arterial compared with hepatic venous plasma (for CONT P,0·05; for AA P¼0·10).
Blood water urea concentrations were significantly greater (1·9-fold, P,0·001) for all samples during AMM and AA infusions compared with CONT ( Table 2 ). The increases in either NH 3 or amino acid load to the liver were clearly reflected, not only in urea concentrations, but also in urea release into the hepatic vein (Table 3) . In both cases, liver urea-N appearance was nearly double that observed with CONT infusion (P¼0·026). There was consistent net urea uptake by the PDV, but this was not significantly different between treatments. The PDV uptake represented 47, 53 and 36 % of liver urea production for AMM, CONT and AA treatments respectively. In the case of CONT and AA infusions, removal of urea-N by the digestive tract accounted numerically for more than 95 % of net NH 3 -N PDV appearance, and more than 80 % for treatment AMM.
The proportions of urea-N released by the liver which could be apparently accounted by NH 3 removal were 66, 65 and 51 % for AMM, CONT and AA treatments, with no significant differences. Compared with CONT treatment, the extra liver NH 3 uptake:urea-N output ratio were 0·66 and 0·42 for AMM and AA infusions respectively.
Glutamine concentration and mass transfers
The AA infusion induced a considerable decrease (16 to 26 %, P,0·02 or better) in glutamine concentrations at all sample sites (Table 4) . Net glutamine mass transfers across the PDV and liver were not significantly different between treatments, although both were numerically greater during the AA infusion (NB this mixture did not contain glutamine). differ significantly between infusions (Table 5 ). The [5- 15 N]glutamine enrichment ratios within the three sample sites differed between treatments (Table 5) . Compared with CONT, the AA infusion resulted in a lower portal:arterial ratio (P,0·02) while the hepatic:arterial enrichment ratio for AMM was also reduced (P,0·03).
Glutamine production across the PDV (the sum of absorption from the GIT lumen plus that released from cell turnover) was unaffected by treatment. Glutamine utilization by the liver exceeded that by the PDV (P,0·02), with net splanchnic utilization similar (104 v. 101 mmol/ min) for CONT and AA infusions and these tended to be lower than for the AMM treatment (140 mmol/min; P¼0·22, SED 40·4). Hepatic production of glutamine was less than utilisation for all treatments (P,0·001). Hepatic glutamine production during AMM infusion was significantly greater (P,0·02) than for CONT and AA. As a proportion of whole-body glutamine flux, PDV utilisation was 19 -44 %, while the total splanchnic glutamine utilization was 45 -70 % of total flux.
Enrichments of 15 NH 3 in hepatic artery, hepatic portal vein and hepatic vein were 14, 9 and 10 % those of the respective glutamine values. These values are similar to those derived from comparisons of net glutamine utilisation with NH 3 absorption (5 -12 %) across the digestive tract. Nonetheless, this appearance of labelled NH 3 for all three treatments (Table 6 ) was the equivalent of 70 -115 % 15 N extracted as glutamine. Across the liver, 15 NH 3 was removed, with the amounts similar across all treatments, despite the differences in net NH 3 movements (cf. Fig. 1 ). The [
15 N]urea enrichment was higher during the CONT infusion in all the vessels sampled, when compared with the other two treatments, but significant only against AA values (P,0·05; Fig. 1 ).
For AMM and CONT treatments there was net removal of [ 15 N]urea by the PDV (Table 6 ). In contrast, PDV [ 15 N]urea utilisation was lower (P,0·02) and close to zero for the AA infusion. The amount of 15 N transferred to the PDV as urea was approximately 0·5 that absorbed as NH 3 . For all three treatments, there was hepatic production of [
15 N]urea, and this was greater (P,0·05) for AMM infusion compared with CONT and AA. The amount of 15 N released from the liver as urea exceeded the amount extracted as glutamine by 30 -100 %, but when 15 NH 3 removal was included as a ureagenic-N precursor, then a more than adequate 15 N balance was achieved (Table 6 ). The amount of 15 N removed as gluta- Mean values within a row with unlike superscript letters were significantly different (P,0·05). * For details of infusions and procedures, see p. 358. † Based on one-way ANOVA, 10 residual d.f. mine plus NH 3 , relative to that released as urea, was greater (P,0·05) for AA compared with CONT and AMM infusions. These latter calculations are based on only four animals, because it was not possible to determine 15 NH 3 enrichments in two sheep.
Discussion
Metabolic principles
The complex interactions between liver removal of NH 3 and amino acids with urea production and glutamine metabolism are achieved through the unique architecture of the liver. The majority of hepatocytes are periportal and contain the enzymes of the ornithine cycle along with mitochondrial glutaminase. Glutaminolysis helps maintain high concentrations of intra-mitochondrial NH 3 , necessary for the continuous synthesis of carbamoyl phosphate (Meijer et al. 1985) . Synthesis of urea involves input of one N atom via carbamoyl phosphate and another N atom through aspartate. If aspartate-N is in excess then extra NH 3 can be produced by glutaminolysis. The less abundant perivenous cells lack glutaminase and the ornithine-cycle enzymes, but instead contain cytosolic glutamine synthetase. When NH 3 supply exceeds the capacity of the ornithine cycle (periportal) then this is used as a substrate for glutamine synthesis (perivenous). Therefore, excess NH 3 supply may lead to an increase in glutamine synthesis , while amino acid excess may increase hepatic glutamine use (Häussinger, 1990; Wray-Cahen et al. 1997) . Both mechanisms may alter glutamine status for other metabolic functions within the liver or other tissues.
Whole-body glutamine metabolism
In sheep, most (.90 %) of the glutamine in whole blood is present in the plasma (N Roy and G Lobley, unpublished results), whereas a large fraction is present in erythrocytes of human subjects (Darmaun et al. 1986 ).
In the current study, therefore, plasma transfers will represent the majority of inter-organ exchanges. Despite the relatively large excess of NH 3 and amino acids wholebody 5-N glutamine fluxes were unaltered, even though there was a marked decrease in arterial glutamine during AA treatment. Such a decrease may reflect either lowered production (release) or increased utilisation by tissues (e.g. the liver). Whole-body glutamine fluxes were similar (256 -272 mmol/kg per h) to those observed in human subjects (268 -283 mmol/kg per h; Darmaun et al. 1986 ), but considerably lower than those found in rats (900 -1300 mmol/kg per h; Squires & Brosnan, 1983 ; for review see Curthoys & Watford, 1995 ) basis. This suggests that flow of recycled glutamine (i.e. converted to glutamate and then resynthesised) through the plasma pool may occur in the sheep, conserving the C skeleton but exchanging the amido-N.
The current values for fed sheep are greater than observed for the 24 h fasted ovine (175 mmol/kg per h; 432 mmol/kg 0·75 per h; Gate et al. 1999) , indicating that nutritional state does alter the inter-organ fluxes of the amido-N of glutamine. Because there is little net absorption of glutamine, the ILR differences can reflect changes in metabolism of tissues beyond the digestive tract (AMM and CONT treatments). However, PDV tissues could be implicated as well in the ILR change, as can be deduced from the numerical effect obtained in both net and total portal fluxes obtained with treatment AA. This is contrary to the findings of Heitmann & Bergman (1978) for the C skeleton, but supports results for human subjects, where inter-organ glutamine metabolism responds markedly to starvation as well as several pathophysiological situations, e.g. metabolic acidosis, critical illness and catabolic diseases (Souba, 1991) . Certainly, the peripheral tissues contribute to both glutamine release and synthesis (fat, Frayn et al. 1991; muscle, lungs and kidneys, Curthoys & Watford, 1995) , as could be indicated by the higher numerical concentrations in arterial compared with hepatic venous plasma.
Glutamine splanchnic metabolism
The gastrointestinal tract is an avid net consumer of glutamine. In the rat, these tissues have little capacity to synthesise glutamine, but contain high glutaminase activity, particularly in the mucosa of the small intestine (James et al. 1998) . The pancreas and gut lymphatic tissue also utilise substantial amounts of glutamine (Souba, 1991) . During AMM and CONT treatments, all dietary and some systemic glutamine was removed by the digestive tract. In fed and fasted sheep, the arterio-venous net utilisations were the same (Heitmann & Bergman, 1978) , i.e. apparent removal from arterial sources was independent of intake. Nonetheless, total utilisation by the digestive tract must have been greater in the fed state, due to glutamine available from the diet. These earlier results implied there was an obligate need by the tissues of the digestive tract for arterial glutamine (e.g. to support serosal metabolism). In contrast, fasted lambs (Gate et al. 1999) showed greater rates of extraction (245 mmol/min) from the arterial inflow than the CONT sheep (1 mmol/min) in the current study. As the diet will provide approximately 30 mmol digestible glutamine, these results suggest an absolute need by the gut that can be met by appropriate combinations of dietary and arterial sources. The reduced glutamine uptake from plasma by the basolateral membranes of the digestive tract tissue during AA infusion (as reflected by the numerically higher glutamine appearance), may be associated with the lower arterial concentrations, as rate of delivery is a known regulator of transport (Rennie et al. 1994) . Alternatively, some of the metabolic functions that glutamine fulfils may be substituted by other amino acids present in the AA infusate. For example, use of the glutamine C skeleton for synthesis of other nonessential amino acids (e.g. alanine, proline; Windmueller & Spaeth, 1980) may be 'spared' due to their exogenous provision.
Gross utilisations across the PDV followed the same pattern as net uptake and values from CONT and AMM animals were similar to other results (2·75 -3·96 mmol/kg 0·75 per min; Heitmann & Bergman, 1978; Gate et al. 1999) . The gastrointestinal tract contributed 0·19-0·44 to wholebody glutamine ILR. The values for CONT and AMM treatments are slightly higher than that obtained from C-skeleton fluxes (0·43 and 0·44 respectively, v. 0·33-0·39; Heitmann & Bergman, 1978) and clearly below for AA infusion (0·19). The values were also below that observed for the amido-N ILR in fasted lambs (0·47; Gate et al. 1999) , although absolute PDV utilisation was similar between the two studies (243 v. 245 mmol/min from CONT treatment). The comparison of the present study against control animals would suggest that glutamine metabolism is more sensitive to intake in non-PDV rather than PDV tissues.
The current results emphasise the ability of the liver to function both as a consumer and producer of glutamine. The numerical increases in hepatic glutamine utilisation (by 35 -45 % above basal conditions) during both AA (NS) and AMM administration, at first, might appear contradictory. For AA infusion, provision of additional NH 3 in the liver mitochondria (via glutaminase action) is necessary to ensure an equal supply of carbamoyl phosphate when aspartate inflows to the ornithine cycle are augmented during deamination of amino acids. This hepatic use of glutamine could be reflected by a decrease in plasma concentrations. Paradoxically, hepatic glutaminase activity can also be augmented when the NH 3 supply is increased (as with AMM infusion). Indeed, for the perfused rat liver, addition of NH 3 stimulated the production of urea from glutamine by 2-fold (Taylor & Rennie, 1988) . This process again involves ensuring that flows of N atoms into the ornithine cycle are matched. In ruminant animals, much of the excess NH 3 -N is converted into glutamate and, subsequently, aspartate (Luo et al. 1995; Milano et al. 2000) .
Liver glutamine production represented 0·17-0·30 whole-body ILR, again lower than values reported previously for [
14 C]glutamine kinetics (0·38; Heitmann & Bergman, 1978) . Hepatic production of glutamine was significantly elevated during the AMM infusion, this probably reflects the role of the perivenous cells as the final, high affinity scavenger, to ensure that post-hepatic blood has low NH 3 concentration. Nonetheless, this remained the minor route for NH 3 removal and only accounted for 6 % of hepatic extraction (NB this contribution would be doubled if the glutamine were synthesised from 2-oxoglutarate rather than from glutamate).
Despite the dynamic responses to AMM and AA supplementation, there were numerical changes in net transfers of glutamine across the liver, but not significantly different from control. This appears to contradict the suggestion for non-ruminant animals that ureagenic removal of excess amino acids will result in utilisation of glutamine (Häussinger, 1990) . Rather, there is an elevation of the intra-hepatic glutamine cycle, but where increased utilisation by the periportal cells is counterbalanced by additional synthesis within the perivenous hepatocytes. Other studies present a confused picture with respect to net utilisation of glutamine to support amino acid catabolism. For example, in pregnant cows, acute (6 h) infusion of L-amino acids into the mesenteric vein increased liver output of urea and net uptake glutamine (Wray-Cahen et al. 1997) . In contrast, a similar study in sheep elevated ureagenesis but not glutamine extraction . In other ovine experiments, liver glutamine extraction was unaffected by changes in either the amount (Heitmann & Bergman, 1978) or quality of diet offered. Hepatic production of glutamine was observed with NH 4 Cl infusions but this involved mildly acidotic conditions . One explanation for these differences between studies may involve the relative inputs of amino acids and NH 3 to the liver. For example, in the current study, for the basal diet (CONT) NH 3 was dominant contributor (65 %) to liver urea-N synthesis. Even when amino acid supply was doubled (AA treatment), NH 3 -N removal by the liver was still 51 % of urea-N output. Therefore, the experimental conditions may not have been extreme enough to create a net demand on glutamine.
Urea and ammonia kinetics
Based on the capacity of the ornithine cycle in ruminant animals (2 mmol urea N/g liver per min; Symonds et al. 1981; Orzechowski et al. 1987) , and a liver mass of 1·6 -1·9 % of live weight (Lobley et al. 1994) 15 N]urea synthesis, while glutamine would provide up to 50 -76 %. Of course, NH 3 is still the predominant ureagenic precursor, but because of the much lower enrichment than glutamine in the current study makes a smaller contribution to 15 N transfers. In rat hepatocytes in vitro, the amido-N of glutamine provides up to 65 % urea-N, when present either as the sole substrate or in a medium that simulated the extracellular fluid (Nissim et al. 1992) . Such extremes are unlikely to operate in vivo, but show the potential importance of glutaminolysis in maintaining ornithine-cycle activity during conditions of metabolic stress.
Urea entry to the digestive tract ranged from 36 -53 % of hepatic production, in the lower range of values reported for ruminant animals (Lapierre & Lobley, 2001 ). This contribution of N to the digestive tract was similar (83 -104 %) to the amount absorbed as NH 3 . In practice, however, usually only 30-50 % of absorbed NH 3 is derived from such urea sources (Sarraseca et al. 1998) , thus other metabolites are important precursors of NH 3 . In the fasted rodent, 40 % of metabolised glutamine-N is absorbed as NH 3 (Windmueller & Spaeth, 1980) but, in both fasted (Gate et al. 1999 ) and fed (current study) sheep, only 5-10 % of the NH 3 is derived from the amido-N of glutamine. This represents less than 25 % of the glutamine amido-N extracted from the arterial plasma and supports the concept that glutamine metabolism is directed towards anabolic fates, such as synthesis of nucleic acids and proteins, in the digestive tract tissues of ruminant animals (Gate et al. 1999) .
The incremental increases in hepatic urea-N production for AMM and AA (675 and 644 mmol/min compared with CONT) were greater than the additional liver removals of NH 3 (310 and 155 mmol/min respectively). Thus, other N-sources, probably amino acids, were required to support ureagenesis during both infusions. While this is understandable for the AA treatment, such extra demands during AMM infusion again raises the issue of whether NH 3 detoxification involves additional amino acid catabolism (cf. Parker et al. 1995; Lobley & Milano, 1997) .
In conclusion, splanchnic glutamine utilisation was shown to account for the majority of whole-body plasma glutamine flux, under conditions which simulated nutritional extremes in ruminant animals. The PDV tissues had a lower demand for glutamine when amino acids were infused, indicative of sparing by other metabolites. Hepatic glutamine utilisation increased during both NH 3 and amino acid infusion, while production increased by 40 %, compared with basal conditions, when ammonium bicarbonate was infused. This provided an effective strategy to prevent peripheral hyperammonaemia. Peripheral glutamine production contributed to the balance of whole-body glutamine metabolism and varied with the form of nutrient supply.
